Abivax (ABVX) Stock Price, News & Analysis

Company Overview

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B.

With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide.

Key Stats

• Today's Range: $125.64 to $127.63
• 50-Day Range: $72.50 to $144.65
• 52-Week Range: $67.15 to $148.83
• Volume: 394,383 shs
• Average Volume: 1.51 million shs
• Market Capitalization: $11.11 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $156.50
• Consensus Rating: Moderate Buy

Abivax Stock Analysis - MarketRank™

Abivax scored higher than 79% of companies evaluated by MarketBeat, and ranked 118th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Abivax has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Abivax has a consensus price target of $156.50, representing about 24.0% upside from its current price of $126.22.

Amount of Analyst Coverage

Abivax has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Abivax are expected to decrease in the coming year, from ($3.22) to ($3.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Abivax is -24.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Abivax is -24.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Abivax has a P/B Ratio of 19.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.61% of the float of Abivax has been sold short.

Short Interest Ratio / Days to Cover

Abivax has a short interest ratio ("days to cover") of 2.36, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Abivax has recently decreased by 7.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Abivax does not currently pay a dividend.

Dividend Growth

Abivax does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.45

News Sentiment

Abivax has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Abivax this week, compared to 6 articles on an average week.

Search Interest

Only 7 people have searched for ABVX on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.

MarketBeat Follows

5 people have added Abivax to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Abivax insiders have not sold or bought any company stock.

Percentage Held by Institutions

47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/22/2026
• Today: 8/06/2026
• Next Earnings (Estimated): 9/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ABVX
• Previous Symbol: NASDAQ:ABVX
• CIK: 1956827
• Web: www.abivax.com
• Phone: 33-1-53-83-09-63
• Fax: N/A
• Employees: 61
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Abivax: $156.50
• High Price Target: $187.00
• Low Price Target: $110.00
• Potential Upside/Downside: +23.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$380.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -99.02%
• Return on Assets: -70.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.25
• Quick Ratio: 8.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.57 per share
• Price / Book: 19.31

Miscellaneous

• Outstanding Shares: 87,254,000
• Free Float: N/A
• Market Cap: $11.07 billion
• Optionable: Not Optionable
• Beta: 1.03